Global Balantidiasis Market

Balantidiasis Comprehensive Study by Type (Tetracycline, Iodoquinol, Metronidazole, Others), Application (Hospitals, Diagnostic Centers, Clinics, Others) Players and Region - Global Market Outlook to 2028

Balantidiasis Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Balantidiasis Market Scope
Balantidiasis is the infection caused by the Balantidium coli, which is the intestinal protozoan parasite. Humans and other mammals can become infected with Balantidium coli by ingesting infective cysts from water and food that is contaminated by feces. Mostly asymptomatic, Balantidium infection can cause such symptoms as abdominal pain and diarrhea. Balantidium coli is found throughout the world, but it is most prevalent in tropical and subtropical regions and developing nations. Because pigs are an animal reservoir, human infections occur more commonly in areas where pigs are raised, especially if good hygiene is not practiced. Tetracycline, a common antibiotic drug, is commonly prescribed in the treatment of Balantidiasis

According to AMA, the Global Balantidiasis market is expected to see growth rate of 2.0%

In this market, companies are completely focused on research and development to develop drugs or devices. The companies are exploring the market in new regions by expansions, investments, collaboration, and partnership as their preferred strategies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Balantidiasis market throughout the predicted period.

Fougera Pharmaceuticals Inc. (United States), Koninklijke Philips N.V. (Netherlands), Johnson & Johnson Services Inc., Abbott (United States), Medtronic (Ireland), Pfizer Inc. (United States), Nurotron Biotechnology Co. Ltd., Sonova Holding AG (Switzerland), C.R. Bard Inc., 3M (United States) and NuVasive, Inc. are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Microport Scientific Corporation (China), Akorn, Inc. (United States), Globus Medical, Inc., Sandoz International GmbH (Germany) and MED-EL (Austria).

Segmentation Overview
The study have segmented the market of Global Balantidiasis market by Type (Tetracycline, Iodoquinol, Metronidazole and Others), by Application (Hospitals, Diagnostic Centers, Clinics and Others) and Region with country level break-up.

On the basis of geography, the market of Balantidiasis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Upsurging Demand for Antibiotics for the Balantidiasis Treatment

Market Growth Drivers:
Increasing Prevalence of Gastrointestinal Disorders and Availability of Treatment of Balantidiasis

Challenges:
The Dearth of Skilled Healthcare Providers and Adverse Effects Associated with Drugs

Restraints:
Competition among Existing Market Players

Opportunities:
Rising Awareness about the Diseases Transmitted Through Fecal-Oral Route, Growing Demand for Balantidiasis Prevalence’s across the Developing Nations, and Rise in prevalence of balantidiasis infection, surge in the trend of swine farming , increase in analysis & development activities for the diagnosis of the disease

Market Leaders and their Expansionary Development Strategies
Medtronic plc, the global leader in medical technology, announced that it has completed its friendly tender offer for France-based Medicrea International a pioneer in the transformation of spinal surgery through artificial intelligence (AI), predictive modeling and patient specific implants.
Abbott has launched its third test for coronavirus (COVID-19) and is shipping tests to hospitals across the U.S. The test is a serology test – also called an antibody test – which could be a critical next step in battling this virus.


Key Target Audience
Drug Manufacturers, Drug Suppliers, Medical Research Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Potential Investors and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Tetracycline
  • Iodoquinol
  • Metronidazole
  • Others
By Application
  • Hospitals
  • Diagnostic Centers
  • Clinics
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Gastrointestinal Disorders
      • 3.2.2. Availability of Treatment of Balantidiasis
    • 3.3. Market Challenges
      • 3.3.1. The Dearth of Skilled Healthcare Providers
      • 3.3.2. Adverse Effects Associated with Drugs
    • 3.4. Market Trends
      • 3.4.1. Upsurging Demand for Antibiotics for the Balantidiasis Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Balantidiasis, by Type, Application and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Balantidiasis (Value)
      • 5.2.1. Global Balantidiasis by: Type (Value)
        • 5.2.1.1. Tetracycline
        • 5.2.1.2. Iodoquinol
        • 5.2.1.3. Metronidazole
        • 5.2.1.4. Others
      • 5.2.2. Global Balantidiasis by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Diagnostic Centers
        • 5.2.2.3. Clinics
        • 5.2.2.4. Others
      • 5.2.3. Global Balantidiasis Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Balantidiasis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Fougera Pharmaceuticals Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Koninklijke Philips N.V. (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson Services Inc.
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medtronic (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nurotron Biotechnology Co. Ltd.
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sonova Holding AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. C.R. Bard Inc.
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. 3M (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. NuVasive, Inc.
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Balantidiasis Sale, by Type, Application and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Balantidiasis (Value)
      • 7.2.1. Global Balantidiasis by: Type (Value)
        • 7.2.1.1. Tetracycline
        • 7.2.1.2. Iodoquinol
        • 7.2.1.3. Metronidazole
        • 7.2.1.4. Others
      • 7.2.2. Global Balantidiasis by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Diagnostic Centers
        • 7.2.2.3. Clinics
        • 7.2.2.4. Others
      • 7.2.3. Global Balantidiasis Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Balantidiasis: by Type(USD Million)
  • Table 2. Balantidiasis Tetracycline , by Region USD Million (2017-2022)
  • Table 3. Balantidiasis Iodoquinol , by Region USD Million (2017-2022)
  • Table 4. Balantidiasis Metronidazole , by Region USD Million (2017-2022)
  • Table 5. Balantidiasis Others , by Region USD Million (2017-2022)
  • Table 6. Balantidiasis: by Application(USD Million)
  • Table 7. Balantidiasis Hospitals , by Region USD Million (2017-2022)
  • Table 8. Balantidiasis Diagnostic Centers , by Region USD Million (2017-2022)
  • Table 9. Balantidiasis Clinics , by Region USD Million (2017-2022)
  • Table 10. Balantidiasis Others , by Region USD Million (2017-2022)
  • Table 11. South America Balantidiasis, by Country USD Million (2017-2022)
  • Table 12. South America Balantidiasis, by Type USD Million (2017-2022)
  • Table 13. South America Balantidiasis, by Application USD Million (2017-2022)
  • Table 14. Brazil Balantidiasis, by Type USD Million (2017-2022)
  • Table 15. Brazil Balantidiasis, by Application USD Million (2017-2022)
  • Table 16. Argentina Balantidiasis, by Type USD Million (2017-2022)
  • Table 17. Argentina Balantidiasis, by Application USD Million (2017-2022)
  • Table 18. Rest of South America Balantidiasis, by Type USD Million (2017-2022)
  • Table 19. Rest of South America Balantidiasis, by Application USD Million (2017-2022)
  • Table 20. Asia Pacific Balantidiasis, by Country USD Million (2017-2022)
  • Table 21. Asia Pacific Balantidiasis, by Type USD Million (2017-2022)
  • Table 22. Asia Pacific Balantidiasis, by Application USD Million (2017-2022)
  • Table 23. China Balantidiasis, by Type USD Million (2017-2022)
  • Table 24. China Balantidiasis, by Application USD Million (2017-2022)
  • Table 25. Japan Balantidiasis, by Type USD Million (2017-2022)
  • Table 26. Japan Balantidiasis, by Application USD Million (2017-2022)
  • Table 27. India Balantidiasis, by Type USD Million (2017-2022)
  • Table 28. India Balantidiasis, by Application USD Million (2017-2022)
  • Table 29. South Korea Balantidiasis, by Type USD Million (2017-2022)
  • Table 30. South Korea Balantidiasis, by Application USD Million (2017-2022)
  • Table 31. Taiwan Balantidiasis, by Type USD Million (2017-2022)
  • Table 32. Taiwan Balantidiasis, by Application USD Million (2017-2022)
  • Table 33. Australia Balantidiasis, by Type USD Million (2017-2022)
  • Table 34. Australia Balantidiasis, by Application USD Million (2017-2022)
  • Table 35. Rest of Asia-Pacific Balantidiasis, by Type USD Million (2017-2022)
  • Table 36. Rest of Asia-Pacific Balantidiasis, by Application USD Million (2017-2022)
  • Table 37. Europe Balantidiasis, by Country USD Million (2017-2022)
  • Table 38. Europe Balantidiasis, by Type USD Million (2017-2022)
  • Table 39. Europe Balantidiasis, by Application USD Million (2017-2022)
  • Table 40. Germany Balantidiasis, by Type USD Million (2017-2022)
  • Table 41. Germany Balantidiasis, by Application USD Million (2017-2022)
  • Table 42. France Balantidiasis, by Type USD Million (2017-2022)
  • Table 43. France Balantidiasis, by Application USD Million (2017-2022)
  • Table 44. Italy Balantidiasis, by Type USD Million (2017-2022)
  • Table 45. Italy Balantidiasis, by Application USD Million (2017-2022)
  • Table 46. United Kingdom Balantidiasis, by Type USD Million (2017-2022)
  • Table 47. United Kingdom Balantidiasis, by Application USD Million (2017-2022)
  • Table 48. Netherlands Balantidiasis, by Type USD Million (2017-2022)
  • Table 49. Netherlands Balantidiasis, by Application USD Million (2017-2022)
  • Table 50. Rest of Europe Balantidiasis, by Type USD Million (2017-2022)
  • Table 51. Rest of Europe Balantidiasis, by Application USD Million (2017-2022)
  • Table 52. MEA Balantidiasis, by Country USD Million (2017-2022)
  • Table 53. MEA Balantidiasis, by Type USD Million (2017-2022)
  • Table 54. MEA Balantidiasis, by Application USD Million (2017-2022)
  • Table 55. Middle East Balantidiasis, by Type USD Million (2017-2022)
  • Table 56. Middle East Balantidiasis, by Application USD Million (2017-2022)
  • Table 57. Africa Balantidiasis, by Type USD Million (2017-2022)
  • Table 58. Africa Balantidiasis, by Application USD Million (2017-2022)
  • Table 59. North America Balantidiasis, by Country USD Million (2017-2022)
  • Table 60. North America Balantidiasis, by Type USD Million (2017-2022)
  • Table 61. North America Balantidiasis, by Application USD Million (2017-2022)
  • Table 62. United States Balantidiasis, by Type USD Million (2017-2022)
  • Table 63. United States Balantidiasis, by Application USD Million (2017-2022)
  • Table 64. Canada Balantidiasis, by Type USD Million (2017-2022)
  • Table 65. Canada Balantidiasis, by Application USD Million (2017-2022)
  • Table 66. Mexico Balantidiasis, by Type USD Million (2017-2022)
  • Table 67. Mexico Balantidiasis, by Application USD Million (2017-2022)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Balantidiasis: by Type(USD Million)
  • Table 80. Balantidiasis Tetracycline , by Region USD Million (2023-2028)
  • Table 81. Balantidiasis Iodoquinol , by Region USD Million (2023-2028)
  • Table 82. Balantidiasis Metronidazole , by Region USD Million (2023-2028)
  • Table 83. Balantidiasis Others , by Region USD Million (2023-2028)
  • Table 84. Balantidiasis: by Application(USD Million)
  • Table 85. Balantidiasis Hospitals , by Region USD Million (2023-2028)
  • Table 86. Balantidiasis Diagnostic Centers , by Region USD Million (2023-2028)
  • Table 87. Balantidiasis Clinics , by Region USD Million (2023-2028)
  • Table 88. Balantidiasis Others , by Region USD Million (2023-2028)
  • Table 89. South America Balantidiasis, by Country USD Million (2023-2028)
  • Table 90. South America Balantidiasis, by Type USD Million (2023-2028)
  • Table 91. South America Balantidiasis, by Application USD Million (2023-2028)
  • Table 92. Brazil Balantidiasis, by Type USD Million (2023-2028)
  • Table 93. Brazil Balantidiasis, by Application USD Million (2023-2028)
  • Table 94. Argentina Balantidiasis, by Type USD Million (2023-2028)
  • Table 95. Argentina Balantidiasis, by Application USD Million (2023-2028)
  • Table 96. Rest of South America Balantidiasis, by Type USD Million (2023-2028)
  • Table 97. Rest of South America Balantidiasis, by Application USD Million (2023-2028)
  • Table 98. Asia Pacific Balantidiasis, by Country USD Million (2023-2028)
  • Table 99. Asia Pacific Balantidiasis, by Type USD Million (2023-2028)
  • Table 100. Asia Pacific Balantidiasis, by Application USD Million (2023-2028)
  • Table 101. China Balantidiasis, by Type USD Million (2023-2028)
  • Table 102. China Balantidiasis, by Application USD Million (2023-2028)
  • Table 103. Japan Balantidiasis, by Type USD Million (2023-2028)
  • Table 104. Japan Balantidiasis, by Application USD Million (2023-2028)
  • Table 105. India Balantidiasis, by Type USD Million (2023-2028)
  • Table 106. India Balantidiasis, by Application USD Million (2023-2028)
  • Table 107. South Korea Balantidiasis, by Type USD Million (2023-2028)
  • Table 108. South Korea Balantidiasis, by Application USD Million (2023-2028)
  • Table 109. Taiwan Balantidiasis, by Type USD Million (2023-2028)
  • Table 110. Taiwan Balantidiasis, by Application USD Million (2023-2028)
  • Table 111. Australia Balantidiasis, by Type USD Million (2023-2028)
  • Table 112. Australia Balantidiasis, by Application USD Million (2023-2028)
  • Table 113. Rest of Asia-Pacific Balantidiasis, by Type USD Million (2023-2028)
  • Table 114. Rest of Asia-Pacific Balantidiasis, by Application USD Million (2023-2028)
  • Table 115. Europe Balantidiasis, by Country USD Million (2023-2028)
  • Table 116. Europe Balantidiasis, by Type USD Million (2023-2028)
  • Table 117. Europe Balantidiasis, by Application USD Million (2023-2028)
  • Table 118. Germany Balantidiasis, by Type USD Million (2023-2028)
  • Table 119. Germany Balantidiasis, by Application USD Million (2023-2028)
  • Table 120. France Balantidiasis, by Type USD Million (2023-2028)
  • Table 121. France Balantidiasis, by Application USD Million (2023-2028)
  • Table 122. Italy Balantidiasis, by Type USD Million (2023-2028)
  • Table 123. Italy Balantidiasis, by Application USD Million (2023-2028)
  • Table 124. United Kingdom Balantidiasis, by Type USD Million (2023-2028)
  • Table 125. United Kingdom Balantidiasis, by Application USD Million (2023-2028)
  • Table 126. Netherlands Balantidiasis, by Type USD Million (2023-2028)
  • Table 127. Netherlands Balantidiasis, by Application USD Million (2023-2028)
  • Table 128. Rest of Europe Balantidiasis, by Type USD Million (2023-2028)
  • Table 129. Rest of Europe Balantidiasis, by Application USD Million (2023-2028)
  • Table 130. MEA Balantidiasis, by Country USD Million (2023-2028)
  • Table 131. MEA Balantidiasis, by Type USD Million (2023-2028)
  • Table 132. MEA Balantidiasis, by Application USD Million (2023-2028)
  • Table 133. Middle East Balantidiasis, by Type USD Million (2023-2028)
  • Table 134. Middle East Balantidiasis, by Application USD Million (2023-2028)
  • Table 135. Africa Balantidiasis, by Type USD Million (2023-2028)
  • Table 136. Africa Balantidiasis, by Application USD Million (2023-2028)
  • Table 137. North America Balantidiasis, by Country USD Million (2023-2028)
  • Table 138. North America Balantidiasis, by Type USD Million (2023-2028)
  • Table 139. North America Balantidiasis, by Application USD Million (2023-2028)
  • Table 140. United States Balantidiasis, by Type USD Million (2023-2028)
  • Table 141. United States Balantidiasis, by Application USD Million (2023-2028)
  • Table 142. Canada Balantidiasis, by Type USD Million (2023-2028)
  • Table 143. Canada Balantidiasis, by Application USD Million (2023-2028)
  • Table 144. Mexico Balantidiasis, by Type USD Million (2023-2028)
  • Table 145. Mexico Balantidiasis, by Application USD Million (2023-2028)
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Balantidiasis: by Type USD Million (2017-2022)
  • Figure 5. Global Balantidiasis: by Application USD Million (2017-2022)
  • Figure 6. South America Balantidiasis Share (%), by Country
  • Figure 7. Asia Pacific Balantidiasis Share (%), by Country
  • Figure 8. Europe Balantidiasis Share (%), by Country
  • Figure 9. MEA Balantidiasis Share (%), by Country
  • Figure 10. North America Balantidiasis Share (%), by Country
  • Figure 11. Global Balantidiasis share by Players 2022 (%)
  • Figure 12. Global Balantidiasis share by Players (Top 3) 2022(%)
  • Figure 13. Global Balantidiasis share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Fougera Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Fougera Pharmaceuticals Inc. (United States) Revenue: by Geography 2022
  • Figure 17. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 18. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2022
  • Figure 19. Johnson & Johnson Services Inc. Revenue, Net Income and Gross profit
  • Figure 20. Johnson & Johnson Services Inc. Revenue: by Geography 2022
  • Figure 21. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 22. Abbott (United States) Revenue: by Geography 2022
  • Figure 23. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 24. Medtronic (Ireland) Revenue: by Geography 2022
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Nurotron Biotechnology Co. Ltd. Revenue, Net Income and Gross profit
  • Figure 28. Nurotron Biotechnology Co. Ltd. Revenue: by Geography 2022
  • Figure 29. Sonova Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Sonova Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 31. C.R. Bard Inc. Revenue, Net Income and Gross profit
  • Figure 32. C.R. Bard Inc. Revenue: by Geography 2022
  • Figure 33. 3M (United States) Revenue, Net Income and Gross profit
  • Figure 34. 3M (United States) Revenue: by Geography 2022
  • Figure 35. NuVasive, Inc. Revenue, Net Income and Gross profit
  • Figure 36. NuVasive, Inc. Revenue: by Geography 2022
  • Figure 37. Global Balantidiasis: by Type USD Million (2023-2028)
  • Figure 38. Global Balantidiasis: by Application USD Million (2023-2028)
  • Figure 39. South America Balantidiasis Share (%), by Country
  • Figure 40. Asia Pacific Balantidiasis Share (%), by Country
  • Figure 41. Europe Balantidiasis Share (%), by Country
  • Figure 42. MEA Balantidiasis Share (%), by Country
  • Figure 43. North America Balantidiasis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Fougera Pharmaceuticals Inc. (United States)
  • Koninklijke Philips N.V. (Netherlands)
  • Johnson & Johnson Services Inc.
  • Abbott (United States)
  • Medtronic (Ireland)
  • Pfizer Inc. (United States)
  • Nurotron Biotechnology Co. Ltd.
  • Sonova Holding AG (Switzerland)
  • C.R. Bard Inc.
  • 3M (United States)
  • NuVasive, Inc.
Additional players considered in the study are as follows:
Microport Scientific Corporation (China) , Akorn, Inc. (United States) , Globus Medical, Inc. , Sandoz International GmbH (Germany) , MED-EL (Austria)
Select User Access Type

Key Highlights of Report


Jun 2023 114 Pages 65 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Balantidiasis Market Quantitative research analysis
Global Balantidiasis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Balantidiasis study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Balantidiasis Market is gaining popularity and expected to see strong valuation by 2028 .
According to AMA, the Global Balantidiasis market is expected to see growth rate of xx%.
The Balantidiasis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Balantidiasis Market Report?

Have a Query? Click Here

Other Related Reports

Transverse Myelitis Comprehensive Study by Therapy (Physical therapy, Occupational therapy, Psychotherapy), Treatment (Intravenous steroids, Plasma exchange therapy, Antiviral medication, Pain medica...
$ 3750
Vaginal Candidiasis Comprehensive Study by Treatment (Oral antifungal, Topical imidazole), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online...
$ 3650
Bovine Babesiosis Treatment Comprehensive Study by Type (Blood Tests, PCR Assays, Serology Tests, Others), Application (Research Laboratories, Veterinary Hospitals, Veterinary Clinics, Animal Care Ce...
$ 3650
Breast Lumpectomy Treatment Comprehensive Study by Treatment (Stage I Breast Cancer, Stage II Breast Cancer, DCIS (Ductal Carcinoma in Situ)), End User (Research Institutes and Academic Centers, Hosp...
$ 3450
Aortic Aneurysm Comprehensive Study by Type (Abdominal Aortic Aneurysm (AAA), Thoracic Aortic Aneurysm (TAA)), Application (Ambulatory Surgical Centers, Hospital), Treatment (Endovascular Aneurysm Re...
$ 3500
Retinitis Pigmentosa Comprehensive Study by Treatment (Acetazolamide Medication, Vitamin A palmitate, Retinal implant, Sunglasses), End-users (Hospitals, Clinics, Others), Diagnosis (Genetic Testing,...
$ 3750